PRO155 COST–UTILITY ANALYSIS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB IN GERMAN ADULT OUTPATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.2484
https://www.valueinhealthjournal.com/article/S1098-3015(19)34862-4/fulltext
Section Title :
Section Order :
12171
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34862-4&doi=10.1016/j.jval.2019.09.2484